Medine.co.uk

Mycinor 150 Mg Tablets For Dogs

Revised: April 2012 (Amended pages)

AN: 00006/2012


SUMMARY OF PRODUCT CHARACTERISTICS


1. Name of the veterinary medicinal product


Mycinor 150 mg Tablets for Dogs


2. Qualitative and quantitative composition


Active Substance:

Each tablet contains 150 mg Clindamycin (as Clindamycin Hydrochloride)


For a full list of excipients, see section 6.1.


3. Pharmaceutical form


Tablet.

A white to off-white circular tablet with a score line on one side. The tablet can be divided into equal halves.


4. Clinical Particulars


4.1 Target species


Dogs.


4.2 Indications for use, specifying the target species


Mycinor150 mg Tablets are indicated for use in dogs as follows:


For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with Staphylococcusspp,Streptococcusspp (except Streptococcus faecalis), Bacteroidesspp, Fusobacterium necrophorum, and Clostridium perfringens. To help provide antimicrobial cover during dental procedures.


For the treatment of superficial pyoderma associated with Staphylococcus intermedius.


For the treatment of osteomyelitis, caused by Staphylococcus aureus.


Before Clindamycin therapy is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.


4.3 Contraindications


Do not use in animals that are hypersensitive to preparations containing clindamycin or lincomycin.


Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin by these species may result in severe gastrointestinal disturbance.


4.4 Special Warnings for each target species


None.


4.5 Special precautions for use


Special precautions for use in animals


Clindamycin and erythromycin show parallel resistance. Partial cross-resistance has been demonstrated between clindamycin, erythromycin and other macrolides antibiotics.


During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.


Animals with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.


Special Precautions to be taken by the person administering the veterinary medicinal product to animals


Wash hands after handling tablets.

Care should be taken to avoid accidental ingestion.

In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or label to the doctor.


4.6 Adverse reactions (frequency and seriousness)


Vomiting and diarrhoea have occasionally been observed.


Clindamycin sometimes causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.


4.7 Use during pregnancy, lactation or lay


While high dose studies in rats suggest that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches or breeding male dogs has not been established.



4.8 Interaction with other medicinal products and other forms of interaction


Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. MycinorTablets should be used with caution in animals receiving such agents.


Clindamycin should not be used concomitantly with chloramphenicol or macrolides as they antagonise each other at their site of action at the 50S ribosomal sub-unit.


4.9 Amounts to be administered and administration route


For oral administration only.


For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections in dogs, administer either:



If no clinical response is seen within 4 days, redetermine the diagnosis. To help provide antimicrobial cover during dental procedures, a 10 day course is recommended. This should be initiated five days before dental therapy and continued for five days thereafter. In dogs, treatment may be extended to a maximum of 28 days based on clinical judgement.


2. For the treatment of superficial pyoderma in dogs, administer either:



Therapy of canine superficial pyoderma is usually recommended for 21 days, with extension of therapy based on clinical judgement.


3. For the treatment of osteomyelitis in dogs, administer:


11 mg/kg of bodyweight every 12 hours for a minimum of 28 days


If no clinical response is seen within 14 days, the treatment should be stopped and the diagnosis redetermined.


Overdose (symptoms, emergency procedures, antidotes), if necessary


In a tolerance study a dose rate of 3 times the recommended dose of 11 mg/kg bodyweight of Mycinor150mg Tablets administered twice daily over a period of 30 consecutive days did not demonstrate adverse effects.



Withdrawal period


Not applicable.


5. pharmacological properties


Pharmacotherapeutic group: Anti-infectives for systemic use; Antibacterials for systemic use; Clindamycin.


ATC vet code: QJ01FF01


5.1 Pharmacodynamic properties


MycinorTablets contain Clindamycin hydrochloride. Clindamycin is a semi-synthetic antibiotic produced by 7(S)-chloro substitution of the 7(R)-hydroxy group of the natural antibiotic produced by Streptomyces lincolnensis var lincolnensis.


Mode of Action:

Clindamycin inhibits bacterial protein synthesis at the ribosomal (50s sub-unit) level.


In vitro activity:

Clindamycin has in vitroactivity against the following micro-organisms:


5.2 Pharmacokinetic properties


Absorption:

Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract following oral administration. Effective clindamycin antibacterial serum levels are reached within 30 minutes following administration of the therapeutic dose.


Serum values:

Therapeutic serum levels of clindamycin can be maintained by oral administration of 5.5 mg/kg bodyweight every 12 hours or 11 mg/kg bodyweight every 24 hours; peak serum concentrations are on average reached 75 minutes after oral administration. The biological plasma half-life of clindamycin in the dog is approximately 5 hours. No accumulation of bioactivity has been observed in dogs after several oral administrations.


Metabolism and Excretion:

Extensive research of the metabolism and excretion pattern of clindamycin shows that the parent molecule as well as bioactive and bio-inactive metabolites are excreted via the urine and faeces. Nearly all bioactivity in the serum following oral administration is due to the parent molecule (clindamycin).


6. Pharmaceutical particulars


6.1 List of excipients


Cellulose, microcrystalline (Avicel PH102)

Lactose, Monohydrate

Povidone

Silicon dioxide

Croscarmellose sodium (AcDiSol)

Magnesium stearate


6.2 Incompatibilities


None known.


Shelf life


Shelf-life of the veterinary medicinal product as packaged for sale: 24 months.


Special precautions for storage


Do not store above 25°C.

Store in a dry place.


Nature and composition of immediate packaging


Packs of 150 tablets in polypropylene tubs with low density polyethylene lids and cotton wool wadding.


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Norbrook Laboratories Limited

Station Works

Camlough Road

Newry

Co Down

BT35 6JP


8. MARKETING AUTHORISATION NUMBER(S)


Vm02000/4309


9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION


Date:7 March 2012


10. DATE OF REVISION OF THE TEXT


Date:April 2012



Page 6 of 6